Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17843/rpmesp.2021.382.6756 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictors of Functional Impairment in Severe COVID-19 Patients Two Months After Discharge.
Ther Adv Pulm Crit Care Med
December 2024
Department of Pulmonary and Critical Care Medicine, Hôtel-Dieu de France University, Medical Center (HDFUMC) of the Saint-Joseph University of Beirut (USJ), Beirut, Lebanon.
Background: The Post-COVID-19 Functional Status (PCFS) scale is a validated tool used to measure the functional status of patients discharged from the hospital.
Objectives: To describe the functional limitations of hospitalized COVID-19 patients at the time of discharge and two months afterward, and to identify risk factors associated with functional impairment.
Design: Retrospective study.
Expert Perspective: Management of Relapses in Giant Cell Arteritis.
Arthritis Rheumatol
December 2024
Division of Rheumatology, University of California Los Angeles, Los Angeles, CA, USA.
Giant cell arteritis (GCA) is a relapsing large-vessel vasculitis with risk of serious ischemic manifestations including vision loss and vascular damage in the form of large-artery stenosis, aneurysms and dissections. Approximately 50% of patients treated with glucocorticoid (GC) monotherapy and 30% of patients receiving adjunctive therapy with tocilizumab experience disease relapses, often during the first 2 years after diagnosis. Although most relapses in GCA do not involve life- or organ-threatening presentations and can be controlled successfully, frequent relapses may lead to increased use of GC and consequent treatment-related morbidity, in addition to risk of further vascular damage.
View Article and Find Full Text PDFPerioperative Management of Takayasu Arteritis for Cardiac Surgery - Review and Single-Center Experience.
Circ J
November 2024
Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute.
Article Synopsis
- - Takayasu arteritis (TAK) is a serious condition that affects large blood vessels, leading to issues like blockages and aneurysms; it's primarily treated with glucocorticoids, but new biological drugs like tocilizumab are proving effective.
- - Patients on tocilizumab may face higher surgical complications, such as infection or delayed healing, and typically do not show increased inflammatory markers during infections, making management challenging.
- - There is a lack of guidelines for the best perioperative care for TAK patients needing cardiovascular surgery, but this article proposes a protocol based on recent evidence to help reduce complications in these patients.
Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).
Rev Med Interne
November 2024
Service de Médecine Interne et Immunologie Clinique, CHU de Dijon, Dijon, France.
Article Synopsis
- The purpose of this project was to update the 2016 recommendations regarding the management of immunosuppressants or biologics in patients with giant cell arteritis (GCA).
- A task force of 18 physicians developed 26 validated recommendations after thorough discussion and a >85% consensus process.
- Key recommendations include using subcutaneous tocilizumab (TCZ) as a first-line treatment when glucocorticoid-sparing is needed, initiating TCZ at diagnosis for patients with specific high-risk conditions, and considering TCZ or methotrexate if glucocorticoid discontinuation is not feasible after 12 months.
Predictors of Drug Retention and Survival Rate of bDMARDs in Rheumatoid Arthritis: A Four-Year Real-Life Tunisian Experience.
Mediterr J Rheumatol
September 2024
Rheumatology Department, La Rabta Hospital, Tunis, Tunisia.
Introduction: This study aims to investigate the efficacy and tolerance of biologic disease-modifying anti-rheumatic drug (bDMARDs) in the current management of rheumatoid arthritis (RA) by identifying the retention time and survival rate of bDMARDs.
Materials And Methods: We conducted a retrospective cohort study including Tunisian patients initiating bDMARD treatment between 2016 and 2018 whose data were collected from the National Health Insurance Fund (NHIF). The NHIF is the national office which organises and centralises patients under bDMARDs from all over the country.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!